Company name Intercept Pharmaceuticals, Inc.
Stock symbol ICPT
Class period May 31, 2016 – September 20, 2017
Lead plaintiff deadline November 27, 2017
Court Southern District of New York
Status Under Investigation

NEW YORK, October 11, 2017 – Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) securities between May 31, 2016 and September 20, 2017 (the “Class Period”).  Investors have until November 27, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements and/or failed to disclose that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis (“PBC”). As a result, the Company’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug. When this news was announced, shares of Intercept fell in value materially, which caused investors harm according to the Complaint.

If you purchased or otherwise acquired Intercept securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Join the action by filling out the form below

First name*

Last name*

City, state ZIP code*

Email address*

Daytime phone*

Evening phone

Purchase Date*

No. of Shares*

Purchase Price*

Purchase Date

No. of Shares

Purchase Price

Join action?*
YesNo


Call to provide more information: Tel: (212) 308-5858

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.